A new drug combination from Corcept Therapeutics, relacorilant, has shown potential in treating platinum-resistant ovarian ...

The WHO warns of rising resistance in fungal diseases, posing global health risks. Candida infections are increasingly tough ...

WHO said that fungal diseases, including drug-resistant infections like Candida, are increasingly affecting immunocompromised ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

While finding the exact cause may prove difficult, an expert has said factors such as environment, genetics and even ...

Mirvetuximab soravtansine improved overall survival, progression-free survival, second progression-free survival, and other outcomes.

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

The phase 3 trial showed relacorilant with chemotherapy improved progression-free and overall survival in platinum-resistant ...

The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ovarian cancer progression by 30% compared to ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...